Evaglip 25 mg+5 mg (Tablet)

Title and Categories

• Evaglip Tablet
• Antidiabetic Medication
• Type 2 Diabetes Control

Dosage and Administration

• Recommended dose: 10 mg Empagliflozin and 5 mg Linagliptin once daily
• Increased dose: Dose may be increased to 25 mg Empagliflozin and 5 mg Linagliptin once daily
• Renal impaired patients: Assess renal function before initiating this tablet. Do not initiate this tablet if eGFR is below 45 mL/min/1.73 m2. Discontinue taking this tablet if eGFR falls below 45 ml/min/1.73 m2

Indications

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Pharmacology

• Linagliptin inhibits DPP-4 enzyme which declines the incretin hormones glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
• Empagliflozin is an inhibitor of Sodium-glucose co-transporter 2 (SGLT2)

Interaction

• Diuretics
• Insulin or Insulin Secretagogues
• Inducers of P-glycoprotein or CYP3A4 Enzymes
• Positive Urine Glucose Test
• Interference with 1,5-anhydroglucitol (1,5-AG) Assay

Contraindications

• Severe renal impairment, end-stage renal disease, or dialysis
• History of hypersensitivity reaction to Linagliptin or Empagliflozin

Side Effects

• Pancreatitis
• Ketoacidosis
• Volume Depletion
• Urosepsis and Pyelonephritis
• Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues
• Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene)
• Genital Mycotic Infections
• Hypersensitivity Reactions
• Severe and Disabling Arthralgia
• Bullous Pemphigoid
• Heart Failure

Pregnancy & Lactation

• Not recommended during the second and third trimesters of pregnancy

Precautions & Warnings

• Precaution should be taken in some disease conditions like Pancreatitis, Hypotension, Ketoacidosis, Acute kidney injury and impairment in renal function, Urosepsis and Pyelonephritis, Hypoglycemia, Genital Mycotic Infections, Hypersensitivity
• An association between DPP-4 inhibitor treatment and heart failure has been observed in cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class

Overdose Effects

• In the event of an overdose with this tablet, contact Poison Control Center

Therapeutic Class

• Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Storage Conditions

• Store below 30° C temperature. Keep away from light and wet place. Keep out of reach of children

Related Brands

• Emaglin-L 25 mg+5 mg (Tablet) - dbl-pharmaceuticals-ltd
• Emaglin-L 10 mg+5 mg (Tablet) - dbl-pharmaceuticals-ltd
• Glinta Plus 25 mg+5 mg (Tablet) - renata-limited
• Glinta Plus 10 mg+5 mg (Tablet) - renata-limited
• Emparol-L 25 mg+5 mg (Tablet) - drug-international-ltd